Investor Presentaiton
Our Goals for 2024
42
Revenue: maintain rapid growth in overall revenue by continuously promoting clinical advantage of
HANSIZHUANG and HANQUYOU
Profitability: improve P&L level, and consolidate profitability from internal operation
Cashflow: positive OCF generated for three consecutive years; further strengthen organic
growth in 2024 and build strong and health cash flows
R&D: advance late-stage pipeline faster, develop early-stage pipeline with differentiation, and
introduce multiple modality assets to enter clinical stage
Overseas Markets: accelerate HANQUYOU approval in the US and NDA submissions in multiple
overseas countries; advance HANSIZHUANG to be marketed in Europe
Resource Allocation: optimize resource allocation, and improve return on investment of R&D,
manufacturing and commercialization, to assure long-term sustainable growth
O 2024 Henlius.
A Henlius 复宏汉霖View entire presentation